YK-11 (YK-11 (Myostatin Inhibitor / SARM))
A synthetic steroidal compound classified as both a SARM and a myostatin inhibitor. Combines AR partial agonism with follistatin induction.
How it works
Partial androgen receptor agonist that induces follistatin expression, creating dual myostatin inhibition and AR activation.
Key facts
- Molecular weight: 430.54 Da
- Half-life: ~6-10 hours
- Bioavailability: ~70% oral
- Storage: Room temperature, protect from light.
Dosing overview
- Typical dose: 5-10 mg
- Frequency: Once daily
- Duration: 6-8 weeks
- Route: Oral
Reported benefits
- Dual anabolic mechanism
- Follistatin induction
- Oral convenience
- Muscle hardening
Possible side effects
- Liver stress potential
- Testosterone suppression
- Joint dryness
- Hair shedding risk
Research
- YK-11 follistatin induction in myocytes (2018): Increased follistatin expression 4-5x in C2C12 cells, exceeding effects of DHT.
- Selective AR modulation by YK-11 (2019): Tissue-selective anabolic activity with minimal androgenic effects on prostate.
Compare YK-11
Community discussions about YK-11
- Noticed Joint Pain After Starting YK-11 – Any Tips to Ease It? - 4 comments
- ACE-031 trial data from years back still worth a look, what do you think? - 4 comments
- Ask the community about YK-11
Research and educational reference only. Not medical advice.